Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 1,686 Shares

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Martina M.D. Flammer sold 1,686 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total transaction of $120,549.00. Following the transaction, the insider now directly owns 83,111 shares of the company's stock, valued at $5,942,436.50. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, May 16th, Martina M.D. Flammer sold 1,799 shares of Insmed stock. The shares were sold at an average price of $67.53, for a total value of $121,486.47.
• On Thursday, May 15th, Martina M.D. Flammer sold 9,925 shares of Insmed stock. The shares were sold at an average price of $65.47, for a total transaction of $649,789.75.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $570,146.48.

Insmed Price Performance

Shares of INSM traded up $0.66 during trading hours on Friday, hitting $73.40. 631,076 shares of the company were exchanged, compared to its average volume of 2,071,260. The firm has a fifty day simple moving average of $69.25 and a 200-day simple moving average of $73.03. The company has a market capitalization of $13.37 billion, a PE ratio of -13.12 and a beta of 0.80. Insmed Incorporated has a one year low of $55.74 and a one year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period in the prior year, the firm earned ($1.06) EPS. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on INSM. Guggenheim reiterated a "buy" rating and set a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $90.00 target price on shares of Insmed in a research note on Monday, May 12th. Truist Financial raised their price target on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and a consensus price target of $96.73.

Institutional Investors Weigh In On Insmed

Hedge funds have recently modified their holdings of the business. National Bank of Canada FI raised its stake in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 147 shares during the last quarter. M&T Bank Corp raised its position in shares of Insmed by 4.7% during the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 147 shares during the last quarter. Snowden Capital Advisors LLC lifted its stake in shares of Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after buying an additional 158 shares during the period. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company's stock valued at $446,000 after acquiring an additional 186 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.